Onxeo wins important new patent
The French-Danish biotech company Onxeo is about to win a new and extremely important patent for the drug Beleodaq on the US market.
BY BENJAMIN WERNER CHRISTENSEN
The biotech company Onxeo, a merger between Denmark’s Topotarget and France-based BioAlliance Pharma, announced last week that it will see a boost to its IP portfolio on September 16, with new patent rights for the drug Beleodaq (marketed under the name Belinostat in the US) for the treatment of recurrent or refractory peripheral T-cell lymphoma, PTCL.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Topotarget merger clears final hurdles
For abonnenter
